Cystic Fibrosis Foundation invests in Owlstone to develop breath test for Pseudomonas detection
The Cystic Fibrosis Foundation has committed up to US$2.3 million (about £1.7 million) in equity investment to Owlstone Medical for the development of a breath test to detect Pseudomonas aeruginosa (PA) infections in people with cystic fibrosis (CF). The Cambridge-based company announced the investment on March 25, 2025, marking a significant step forward in respiratory […]










